Background. We hypothesized C1q binding de novo donor-specific antibody (DSA) after heart transplant (HT) is a higher risk for development of coronary artery vasculopathy (CAV) in children. Methods. A retrospective analysis of 127 pediatric HT recipients transplanted between January 2005 and December 2014 was used to determine complement (C1q)-binding de novo DSA on the outcomes of HT and the ability of the C1q assay to predict CAV development. Results. Of 127 patients, 59 (46.4%) developed de novo DSA, 37 of those had C1q+ DSA. There was no difference in baseline characteristics except patients who developed C1q+ DSA more often received a donor heart from a female compared with C1q− DSA group (P = 0.034). The DSA median fluorescent intensity (MFI) value of 7000 or greater had 80% sensitivity and 80% specificity (C statistics 0.89, P <0.05) for predicting positive C1q binding. Multivariate analyses identified C1q binding DSA as an independent risk for CAV with a hazard ratio (HR) of 3.25 (95% confidence interval [CI], 1.33-7.93; P = 0.0095). In multivariable Cox proportional hazard models, the covariates associated with graft loss included: C1q+ DSA (HR, 3.2; 95% CI, 1.34-7.86; P < 0.009), pre-HT renal insufficiency (HR, 11.3; 95% CI,; P < 0.0001), and pre-HT ventilator support (HR, 3.3; 95% CI, 1.39-7.81; P = 0.007). Conclusions. The DSA strength in MFI correlates with positive C1q-binding activity and hence functional capabilities of DSA. Close monitoring of DSA strength in MFI and function (C1q assay) may be useful for identifying pediatric HT recipient at risk for development of CAV.
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Background. We hypothesized C1q binding de novo donor-specific antibody (DSA) after heart transplant (HT) is a higher risk for development of coronary artery vasculopathy (CAV) in children. Methods. A retrospective analysis of 127 pediatric HT recipients transplanted between January 2005 and December 2014 was used to determine complement (C1q)-binding de novo DSA on the outcomes of HT and the ability of the C1q assay to predict CAV development. Results. Of 127 patients, 59 (46.4%) developed de novo DSA, 37 of those had C1q+ DSA. There was no difference in baseline characteristics except patients who developed C1q+ DSA more often received a donor heart from a female compared with C1q− DSA group (P = 0.034). The DSA median fluorescent intensity (MFI) value of 7000 or greater had 80% sensitivity and 80% specificity (C statistics 0.89, P <0.05) for predicting positive C1q binding. Multivariate analyses identified C1q binding DSA as an independent risk for CAV with a hazard ratio (HR) of 3.25 (95% confidence interval [CI], 1.33-7.93; P = 0.0095). In multivariable Cox proportional hazard models, the covariates associated with graft loss included: C1q+ DSA (HR, 3.2; 95% CI, 1.34-7.86; P < 0.009), pre-HT renal insufficiency (HR, 11.3; 95% CI, 3.71-34.29; P < 0.0001), and pre-HT ventilator support (HR, 3.3; 95% CI, 1.39-7.81; P = 0.007). T here is equivocal evidence in the literature regarding the role of de novo donor-specific anti-HLA antibodies (DSA) and its association with increased incidence of coronary artery vasculopathy (CAV), acute rejection, and decreased survival in pediatric heart transplant (HT) recipients. Currently, detection of HLA antibodies is routinely performed using single-antigen beads (SAB) with solid-phase assays (SPA). In the last decade, SPA has replaced for the most part lesssensitive cell-based assays. SPA technologies have the advantage of not only determining the presence of HLA antibodies but also the class and specificity. However, SPA may be oversensitive by not distinguishing those DSA with clinical significance. Ho et al 1 have shown that antibody-mediated rejections (AMR) and poor long-term graft survival was associated with DSA identified by the complement-dependent cytotoxicity assay but not by SPA. In our previous study, we showed that DSA-positive patients had significantly higher rate of CAV compared with DSA-negative patients (36% vs 13%), but we did not evaluate the impact of complementbinding and noncomplement-binding DSAs on acute rejections, graft loss, and development of CAV. 2 The capacity of DSA to bind complement fraction C1q, which is the first step in the activation of the classic complement cascade, determines the cytotoxic potential of these antibodies, and an assessment of their complement-binding capacity may be useful for risk stratification. Numerous studies have clearly demonstrated that C1q-binding DSAs are strongly associated with AMR and graft loss in solid organ transplants including heart, 3,4 kidney, 5, 6 and lung 7 transplants. In the most comprehensive analysis to date, Loupy et al 6 found that patients who develop C1q-positive DSA in the first year after renal transplantation, showed worse graft survival than those with C1q-negative (C1q-) DSA (54% vs 93% 5-year graft survival). Zeevi and colleagues 4 showed similar results in HT recipients. However, studies by Yell et al 7 and Tambur et al 8 showed that in fact, C1q binding represents higher levels of DSA and is not necessarily a reflection of a difference in DSA function. We hypothesized that the C1q-binding de novo DSA after pediatric HT is associated with a higher risk for development of CAV. This study aimed, (1) to determine the impact of C1q+ de novo DSA on adverse outcomes in pediatric HT; (2) to find a cutoff value for DSA in median fluorescent intensity (MFI) as predictor of C1q-binding activity (functional ability of DSA); and (3) to evaluate the ability of C1q assay to predict the development of CAV in pediatric HT recipients.
MATERIALS AND METHODS

Patients
This retrospective analysis comprised pediatric HT recipients transplanted at our center between January 2005 and December 2014 and was approved by our institutional review board. All patients included in this study had negative T-and B-cell retrospective flow cytometric crossmatch on post-HT day 0, and no DSA were identified by Luminex SAB assay before transplant. Our SAB tests detected the presence of IgG antibodies but not IgM. In the case of patients who underwent retransplantation, only their first HT outcomes were included in this study. We used the term DSA to describe de novo DSA in the remainder of the article.
All patients received a quadruple sequential immunosuppression. Induction therapy consisted of methyl prednisolone and basiliximab (Simulect, Novartis) in 99% of cases (only 2 patients received antithymocyte globulin). Standard maintenance immunosuppression included triple therapy of tacrolimus/ cyclosporine, mycophenolate mofetil, and steroids. Steroids were routinely withdrawn after 1 year unless there was more than 1 rejection event within the first year after transplant. Patients who developed renal insufficiency or CAV received sirolimus instead of a calcineurin inhibitor. The medical records, pathologic reports, coronary angiograms were reviewed to obtain the baseline characteristics and clinical data.
Donor-Specific Antibodies and C1q Testing
Before 2006, donors and recipients were typed for HLA-A, B, DRB1/3/4/5, and DQB1 using a serological method and/or sequence-specific primer, sequence-specific primer Unitray (Invitrogen Inc.). After 2006, all patients and donors were typed for HLA-A, B, C, DRB1/3/4/5, and DQB1 using sequence-specific oligonucleotide (SSO), LabType SSO (One Lambda, Canoga Park, USA). Some patients and donors typed before 2006 were retyped using SSO or high resolution sequence based typing (in house) when needed to confirm presence of DSA. As needed, patients were also typed for HLA-DQA1 and DPB1.
All patients were tested for the presence of circulating DSA in serum samples collected with each cardiac catheterization and endomyocardial biopsy (EMB) as described in our previous study. 2 Luminex LABScreen Single Antigen beads (One Lambda, Canoga Park, CA) was used to detect class I and class II HLA-antibodies and the intensity of the HLA antigen-antibody interaction was expressed in MFI. We defined patients as having positive DSA only when the DSA was persistent for 2 consecutive samples and DSA MFI was 1000 or greater for this study as previously reported cutoff for "true" antibodies by Chin et al. 3 The negative control bead MFI value was subtracted from each bead MFI value before applying the cutoff to adjust for background. We identified the peak serum samples for the circulating immunodominant DSAs (iDSAs) for each patient with positive DSA. For this study, we analyzed those samples for the presence of C1q-binding DSA per manufacturer's protocol (C1qScreen and LAB Screen Single Antigen, One Lambda). 9 DSAs identified by single-antigen assay with the capacity to bind human C1q were considered to be C1q+ DSA, and those without this capacity were considered C1q-DSA. The positive cutoff for the C1q assay was set at 500 MFI after comparisons were made to the background MFI, and there was a 50% increasing over the background at cutoff values of 500 MFI. Positive and negative control sera were used in this assay as controls.
EMB
Routine surveillance EMBs were performed per our institutional protocol: every 2 weeks for the first 3 months, every month for the next 3 months, at 9 months, and then at 12 months after HT. The frequency of EMB 1 year post-HT was annual unless clinical rejection was suspected. With each annual EMB, hemodynamics from the right and left heart were obtained, coronary angiograms performed and 5 pieces of the right ventricular myocardium were obtained and sent for histopathology.
Acute Rejections
Acute rejection events included all clinical rejections requiring antirejection therapy, acute cellular rejection (ACR) 2R or higher International Society for Heart and Lung Transplantation grade 10 or AMR. Because this was a retrospective study, we did not use the 2013 International Society for Heart and Lung Transplantation guidelines for diagnosis of AMR 11 rather we defined AMR per our institutional practice if the patient had 3 of the following 4 criteria: (1) evidence of graft dysfunction on echocardiogram, (2) positive C4d and CD68 by immunohistochemical stains, (3) biopsy with interstitial edema and endothelial swelling (usually without evidence of ACR), and (4) presence of DSA. Patients, who had acute clinical rejection but had not undergone prior EMB due to hemodynamic instability or those who had EMB proved pathological ACR ≥ 2R, were first treated with intravenous methylprednisolone at 20 mg/kg (maximum 1000 mg) daily for 3 days. We repeated EMB 2 weeks after completion of corticosteroid treatment to confirm resolution of rejection. If there was persistent ACR grade 2R or higher after the first treatment, pulsed intravenous methylprednisolone was repeated. A repeat biopsy was performed at the completion of the second course of steroids. If there was persistence of ACR or the patient had hemodynamically compromising clinical rejection, the patient was treated with antithymocyte globulin (1-1.5 mg/kg per dose for 10-14 doses). For patients who had AMR, the treatment course was rituximab (375 mg/ m 2 IV weekly Â 4 doses) and intravenous immunoglobulin G (1 g/kg per dose every 2 weeks Â 2 doses), followed by a repeat EMB after 4 weeks of completion of rituximab to confirm recovery.
Cardiac Allograft Vasculopathy Screening
The diagnosis of CAV was based on coronary angiography in all patients and in addition 2 patients who had pathologic evidence of CAV on autopsy. For all patients, first coronary angiogram screening for CAV was performed 1-year after HT and annually thereafter. Additional angiograms were performed if there was unexplained graft dysfunction. All angiograms were reviewed retrospectively for evidence of CAV by 1 of the authors (B.D.). For this study, CAV was defined as any new-onset coronary artery stenosis by coronary angiogram irrespective of whether a branch or main vessel was involved.
Graft Loss
Graft loss was defined as patient death or relisting for HT. Relisting for transplantation was considered when a patient developed heart failure due to ventricular dysfunction or life-threatening arrhythmia. The date of relisting was considered as the endpoint of graft loss for those patients who had significant irreversible graft dysfunction (n = 8). All 8 patients who were relisted underwent subsequent retransplantation. Five of the patients who satisfied the above criteria for graft loss were not relisted for transplantation at our center due to social issues or noncompliance, all of whom died and their time of death was included as time of graft loss. Some patients (n = 2) who were considered for relisting but subsequently improved and did not require transplant were not included under graft loss.
Statistical Analysis
Independent t test, analysis of variance, Fisher exact test, and χ 2 test were used to compare variables between groups. The Wilcoxon-Mann-Whitney test was performed when the normality assumption did not hold. Kaplan-Meier curves were constructed to present time to event outcomes. Univariate and multivariate Cox regression models were used to assess risk factors associated with the time to event for graft loss and CAV. Univariate analysis was performed for each covariates: recipient age at transplant, donor age, donor and recipient sex, pretransplant diagnosis (congenital heart disease vs cardiomyopathy), pretransplant panel-reactive antibodies, number of HLA mismatches, previous surgical procedure, pretransplant use of mechanical circulatory support, inotropic support, ventilator support, serum albumin, bilirubin, renal insufficiency (defined as estimated glomerular filtration rate, <50 mL/min per 1.73 m 2 ), withdrawal of steroid at 1 year posttransplant, presence of DSA, strength of DSA in MFI, C1q-positive status of DSA, and era of HT (2005-2010 vs 2011-2014). C1q status and MFI were included as timedependent covariates, such that all subjects were DSAnegative at baseline but some patient became DSA-positive during follow-up, at which point C1q+/− and MFI were determined. Then, covariates with P values less than 0.2 in univariate analysis were retained as candidate predictors for multivariate analysis and stepwise variable selection procedure was performed on the candidate predictors to obtain the final multivariate model. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
A total of 127 patients who underwent primary HT at Children's Medical Center Dallas between 2005 and 2014 were included in the analysis. DSA was detected in 59 of 127 patients after HT. Patients were classified in 3 groups, per the presence or absence of DSA and C1q binding capacity: DSA-negative group (n = 68), C1q+ DSA group (n = 37), and C1q-DSA group (n = 22). Table 1 shows the clinical, laboratory and demographic characteristics of all patients included in this study. No difference in baseline characteristics was noted between those with or without DSA. Patients who developed C1q+ DSA received a donor heart from a female gender more often than a male compared to C1q-DSA group (P = 0.034). Among the 59 patients who were positive for DSA, DSAs were first identified at a median of 689 days post-HT. Of patients with positive DSA, 4 (6.7%) patients had class I DSA (mean MFI, 2653 with 25th to 75th percentile: 1223-4296), 27 (45.7%) patients had class II DSA (mean MFI, 10 784 with 25th to 75th percentile: 4291-15 869) and 28 (47.6%) patients had both Class I and Class II DSA (mean MFI 10 521 with 25th to 75th percentile: 4279-16 200). Among class II HLA antibodies, DQ was prevalent in our cohort. Antibodies against DQB1, DQA1, or combo DQA1/ DQB1 were included under the DQ specificity. The receiveroperating characteristic curve (Figure 1) showed that a DSA at of 7000 MFI or greater identified most C1q-positive cases with an 80% sensitivity and 80% specificity (C statistics, 0.89 and P <0.05). Table 2A showed no significant differences in rejection episodes per patient-year between DSA-negative and C1q-DSA-positive patients (0.5 ± 0.9 vs 0.8 ± 1; P =0.2119). The number of acute rejection events per patient-year between patients who had C1q+ DSA and C1q-DSA were 1.9 ± 1.4 versus 0.8 ± 1, respectively (P = 0.0018). Similarly, patients with DSA of 7000 MFI or greater had 2.0 ± 1.4 rejections per patient year compared with 1 ± 1.1 in patient with DSA MFI less than 7000 MFI (P = 0.0059). The diagnostic accuracy of C1q binding activity and elevated DSA MFI value for detecting acute rejections were comparable (Table 2B) .
Acute Rejections
Cardiac Allograft Vasculopathy
A total of 32 (25.1%) patients developed CAV in the entire cohort during the study period. Patients who were C1q+ DSA had significantly higher frequency of CAV compared with patients with C1q-DSA (51.3% vs 22.7%); P = 0.025 (Table 2A) . When compared with DSA MFI of 7000 or greater, the development of CAV was 51.5% versus 26.9% in DSA MFI less than 7000 (P = 0.174). Freedom from CAV in C1q+ DSA patients was 90%, 70%, and 40% at 1, 5, and 10 years compared with 98%, 75%, and 75% in C1q-DSA patients (P < 0.01, log-rank test) (Figure 2A ). When we analyzed the CAV outcome based on DSA cut-off 7000 MFI, freedom from CAV in patients with DSA of 7000 MFI or greater was 96%, 60%, and 36% at 1, 5, and 10 years compared with 98%, 70%, and 62% in patients with DSA less than 7000 MFI (P = 0.023, log-rank test) ( Figure 2B) .
The results of univariate time-dependent Cox regression analysis for CAV are presented in Table 3 . It demonstrates that developing C1q+ DSA is significantly associated with the risk of CAV (hazard ratio [HR], 3.32; P = 0.004), whereas the risk of development of CAV with DSA MFI is HR of 1.19 (P = 0.53). The final multivariate Cox model identified C1q+ DSA as an independent risk factor for developement of CAV regardless of DSA MFI (HR, 3.25; 95% CI, 1.33-7.93; P = 0.0095). There is an association with presence of DSA greater than 7000 MFI and CAV however C1q positivity provides a higher stratification risk regardless of the MFI level.
Graft Loss
Graft loss occurred in 31 (24.4%) patients. The cause of graft loss was determined by autopsy reports/study of explanted hearts when retransplantation was performed and clinical events from medical chart review when autopsy was not performed, were CAV/acute rejections (87%, n = 27), unknown/ sudden death (6.4%, n = 2), malignancy like posttransplant lymphoproliferative disease, and multisystem failure (6.4%, n = 2). C1q+ DSA patients had significantly higher rates of graft loss [13/37 (35.12%)] compared with C1q-DSA group [2/22 (9.1%); P = 0.0323]. When compared with DSA MFI of 7000 or greater, graft loss was 10 (39.3%) of 33 versus 5 (19.2%) of 26 in DSA less than 7000 MFI (P = 0.549) (Table 2B ). In univariate Cox regression analysis, covariates significantly associated with graft loss included: female sex of donor, acute rejections per patient year, steroid withdrawal at 1 year post-HT, previous cardiac surgical procedures, ventilator at the time of transplant, and renal insufficiency at pretransplantation (Table 4) . However, in the multivariate analysis, only 3 factors were associated with graft loss, namely (1) C1q+ DSA, (2) pretransplant renal insufficiency, and (3) pretransplant ventilator use (Table 5) .
Outcomes of Cases That Were C1q-and DSA of 7000 or Greater Versus Those With C1q+ DSA Less Than 7000 MFI There is a total of 11 patients with discrepancy between C1q-binding activity and DSA MFI strength (C1q-DSA, ≥7000 MFI [n = 3} and C1q+ DSA <7000 MFI [n = 8]). Of these 11 patients, total 7 patients had CAV. C1q+ DSA less than 7000 MFI diagnosed CAV in 3 of 8 and missed only 1 case, whereas C1q-DSA of 7000 MFI or greater diagnosed CAV in 1 of 3 and missed 2 cases of CAV. We compared the adverse outcomes in these 2 groups and various combinations thereof and summarized the data in Table 6 . The results showed that C1q+ DSA less than 7000 MFI and C1q-DSA 7000 MFI or greater both exhibited higher diagnostic value for detection of rejection and graft loss compared with no DSA group. However, the association with CAV is not stronger between C1q+ DSA MFI less than 7000 and/or C1q-DSA Comparisons of adverse outcome of heart transplantation by C1q assay Comparisons of adverse outcome of heart transplantation by DSA strength in MFI Graft loss due to CAV and/or acute rejections is only used in this analysis.
MFI of 7000 or greater versus C1q-DSA MFI less than 7000 and/or C1q+ DSA MFI of 7000 or greater.
DISCUSSION
This retrospective study demonstrated the worse impact of C1q+ DSA on adverse outcomes, such as acute rejections, graft loss, and CAV in pediatric HT recipients. Furthermore, our results showed that DSA strength in 7000 MFI or greater better correlates with C1q positivity, yet the strength itself is not independently associated with adverse outcome on multivariate analysis, more specifically CAV. Although DSA strength measured as MFI value and C1q-binding activity may provide equivalent measure of risk of rejection and graft loss, their ability to predict CAV is lower than C1q+ DSA of 7000 or greater. Previously, Tambur et al 8 have shown that high MFI antibodies does not always suggest "high titer antibody" or correlate with clinical outcomes. On the other hand, Tyan 12 introduced C1q binding as a criterion to stratify pathogenic antibodies using their ability to bind C1q, assuming that this assay identified only those antibodies that have the capacity to bind complement and therefore, those are harmful DSA. Chen and colleagues 13 furthermore showed that C1q+ DSA appear to be more highly correlated than those detected by IgG alone by SAB for AMR in hearts as well as for kidney transplant glomerulpathy and graft failure.
The relative role of C1q+ and C1q-DSA on the development of CAV in pediatric HT recipients is unknown. Previously, Smith et al 14 have described that there was no significant correlation between DSA and CAV, but have shown that a significantly higher number of patients with DSA died of CAV/acute rejections in adult HT patients. Their study did not evaluate the complement binding (C1q-binding) ability of DSA. In our previous study, although we found that DSA had a strong negative impact on posttransplant adverse outcomes after pediatric HT, DSAwas not found to be an independent predictor of CAV in multivariable analysis. 2 In the present study, we showed that detection of C1q+ DSA after HT may support the notion that the complement pathway may play a critical role in acute rejections, CAV, and graft loss. However, these findings do not rule out a possible role for complement-independent mechanisms in acute rejections, CAV, or graft loss mediated by DSA. Identified C1q+ DSA were not subtyped using singleantigen beads to determine whether the complement fixing antibodies were IgG, IgM, or a combination of both. Previously, Chin et al 3 have shown that the C1q assay can detect 4 has reported that C1q binding can risk stratify for pediatric and adults for positive complement-dependent cytotoxicity crossmatch and early AMR in sensitized heart allograft recipients. Therefore, after identifying significant DSA, the addition of C1q assay can be helpful to identify immunologically higher risk for development of CAV in pediatric HT recipients.
Two studies suggested that the value of reported correlation between C1q binding ability and worse graft outcomes may be an indication of DSA strength and not necessarily reflection of their complement-binding abilities. 7, 15 Recently, a study described some of the technical limitations of the C1q SAB assay and showed that antibody level, interfering factors, and the presence of denatured HLA protein on class I SAB may all affect the clinical interpretation of the C1q assay. 16 Tambur and Lavee 17 suggested that titration/dilution studies can provide biologically relevant nuances about HLA antigen-antibody dissociation rates and, therefore, are likely to provide better indication of true antibody strength. The authors suggested that, by performing dilution studies, several interfering factors in the serum which can lead to an underestimation of the level of DSA are diluted in the process and their effect is unmasked; very high levels of DSA that cause oversaturation of the HLA antigens on SAB are no longer a problem because the serum continues to be diluted until negative responses are achieved; the strength ("affinity') of antibody binding can be appreciated by the number of dilutions required to remove antibody from its target. However, these findings have not been validated in larger studies. A criticism raised against the dilution approach is the potential increase in cost similar to the criticism for C1q assay given the substantial additional cost. Ethylenediaminetetraacetic acid pretreatment of serum sample is proposed as a means to remove the interfering factors in serum, thus uncovering prozone effect, and provide a more accurate estimate of antibody strength, but this was not shown to be effective in the studies. 16 The clinical utility of C1q assay using previously stored sera which was freeze/thawed for the C1q assay may be effective in reducing some of those interfering factors but this remains to be validated in future studies.
We acknowledge that this study has several important limitations, beginning with the single center. In our study, we did not perform dilution of serum to test for anti-HLA antibodies. We also did not subclassify the type of IgG HLAantibodies. We tested the C1q reactivity in all peak serum where high levels of donor-specific IgG anti-HLA antibodies were detected using single-antigen assay. However, there is a possibility that we may have missed some complement-binding DSA in samples that did not contain the iDSAs. In all samples tested using the C1q assay, when C1q-positive DSAs were identified, the immunodominant DSA was C1q-positive. We did not perform repeat C1q testing for all DSA for each patient, but instead tested those sera identified as iDSA, we could not determine if there was any conversion of C1q-positive to C1q-negative with change in DSA MFI level. We considered that all patients were DSA-negative at the time of transplant based on the negative retrospective flow cytometric crossmatch results and lack of DSA identified by Luminex LABScreen Single Antigen assay. C1q was not tested pretransplant; presence of IgG DSA would have been detected by SPA but not presence of IgM antibodies. We did not consider the impact of early versus late appearance of DSA and post-HT outcome. Also, we did not study the impact of any change in immunosuppression therapy on DSA or C1q status. In this study, we grouped all types of treated rejection events as acute rejections, and because of the small number of AMR, we were not able to differentiate between ACR and AMR. Another limitation is that CAV may be missed by angiography especially when only small-vessel disease was present. However, a major strength of this study is that it includes patients exposed to a uniform induction and maintenance immunosuppression therapy protocol and had serial cardiac catheterizations, EMBs, and serum samples for testing DSAs. We did not collect data including noncompliance or change in immunosuppressive medications for each patient to identify the cause of the relatively higher percentage of DSA in our cohort.
In conclusion, our study showed that the C1q assay can potentially identify a clinically relevant subset of DSA and 
